**Supplementary Table 1. Additional multivariable analysis of the primary composite outcome of symptomatic VTE (DVT, PE, recurrent or extending SVT\*)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | |  | |  | |
|  |  | | **HR** | | **95% CI** | | **P value** | |
|  |  | |  | |  | |  | |
| After 3 months | | | | | | | | |
|  | Cancer vs no cancer | | 3.66 | | 1.80–7.45 | | <0.001 | |
|  | Age (years) | | 0.97 | | 0.95–0.99 | | 0.004 | |
|  | Previous DVT or PE | | 1.69 | | 0.92–3.09 | | 0.089 | |
|  | Cardiovascular risk factors/diseases | | 0.95 | | 0.54–1.65 | | 0.843 | |
|  | Great saphenous vein only | | 1.49 | | 0.91–2.44 | | 0.111 | |
|  | Varicose veins | | 0.94 | | 0.54–1.62 | | 0.818 | |
|  | Anticoagulation | | 1.15 | | 0.42–3.18 | | 0.788 | |
|  |  | |  | |  | |  | |
| After 12 months | | | | | | | | |
|  | Cancer vs no cancer | | 2.42 | | 1.31–4.50 | | 0.005 | |
|  | Age (years) | | 0.97 | | 0.96–0.99 | | 0.001 | |
|  | Previous DVT or PE | | 1.83 | | 1.16–2.89 | | 0.009 | |
|  | Cardiovascular risk factors/diseases | | 1.11 | | 0.72–1.73 | | 0.629 | |
|  | Great saphenous vein only | | 1.20 | | 0.81–1.78 | | 0.370 | |
|  | Varicose veins | | 1.17 | | 0.74–1.86 | | 0.505 | |
|  | Anticoagulation | | 1.34 | | 0.65–2.78 | | 0.427 | |
| \* Extension into the deep vein system or to < 3 cm of the saphenofemoral junction | | | | | | | |

Abbreviations: **VTE** venous thromboembolism, **DVT** deep vein thrombosis, **PE** pulmonary embolism, **SVT** superficial vein thrombosis, **HR** hazard ratio, **CI** confidence interval

**Supplementary Table 2. Sensitivity analyses of study outcomes according to the timing of cancer diagnosis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | | **Outcomes after 3 months** | | | | | | | |  | **Outcomes after 12 months** | | | | | | | | |
|  |  | | **Patients with known**  **cancer at baseline** | | | | **Patients with known cancer at baseline or cancer diagnosed within 3 months of follow-up** | | | |  | **Patients with known**  **cancer at baseline** | | | | | **Patients with known cancer at baseline or cancer diagnosed within 3 months of follow-up** | | | |
|  |  | | n=70 | | | | n=76 | | | |  | n=70 | | | | | n=76 | | | |
|  |  | | n | | % | | n | | % | |  | n | | | % | | n | | % | |
| Primary outcome |  | |  | |  | |  | |  | |  |  | | |  | |  | |  | |
| Symptomatic VTE (DVT, PE, recurrent or extending\* SVT) | | | 7 | | 10.0 | | 10 | | 13.2 | |  | 9 | | | 12.9 | | 12 | | 15.8 | |
|  |  | |  | |  | |  | |  | |  |  | | |  | |  | |  | |
| Secondary outcomes | |  | |  | |  | |  | |  | | |  |  | |  | |  | |  | |
|  | SVT (recurrent or extending\*) | | 5 | | 7.1 | | 6 | | 7.9 | |  | 7 | | | 10.0 | | 8 | | 10.5 | |
|  | PE | | 0 | | 0.0 | | 2 | | 2.6 | |  | 1 | | | 1.4 | | 3 | | 4.0 | |
|  | DVT | | 3 | | 4.3 | | 3 | | 4.0 | |  | 3 | | | 4.3 | | 3 | | 4.0 | |
|  | DVT and PE | | 2 | | 2.9 | | 4 | | 5.3 | |  | 2 | | | 2.9 | | 4 | | 5.3 | |
|  | Persistent SVT | | 7 | | 10.0 | | 8 | | 10.5 | |  | 7 | | | 10.0 | | 8 | | 10.5 | |
|  | Asymptomatic SVT\*\* | | 0 | | 0.0 | | 0 | | 0.0 | |  | 0 | | | 0.0 | | 0 | | 0.0 | |
|  | Death | | 0 | | 0.0 | | 2 | | 2.6 | |  | 3 | | | 4.3 | | 5 | | 6.6 | |
|  | Hospitalization due to VTE | | 2 | | 2.9 | | 3 | | 4.0 | |  | 2 | | | 2.9 | | 3 | | 4.0 | |
|  |  | |  | |  | |  | |  | |  |  | | |  | |  | |  | |
| Bleeding |  | | 3 | | 4.3 | | 3 | | 4.0 | |  | 3 | | | 4.3 | | 3 | | 4.0 | |
| Severe bleeding |  | | 1 | | 1.4 | | 1 | | 1.3 | |  | 1 | | | 1.4 | | 1 | | 1.3 | |
| Clinically relevant non-major bleeding | | | 2 | | 2.9 | | 2 | | 2.6 | |  | 2 | | | 2.9 | | 2 | | 2.6 | |

\* Extension into the deep vein system or to < 3 cm of the saphenofemoral junction

\*\* Detectable only on compression or duplex ultrasound

\*\*\* Cancer vs no cancer

Abbreviations: **VTE** venous thromboembolism, **DVT** deep vein thrombosis, **PE** pulmonary embolism, **SVT** superficial vein thrombosis